Global Health X (GHX)

The Ganesha Lab is a global life sciences scale-up lab based in Latin America, dedicated to transforming high-potential science-based startups into successful, scalable international businesses. With a focus on strategic mentoring, investor readiness, and global market access, The Ganesha Lab empowers entrepreneurs to drive innovation and improve lives around the world.

Through our deep scientific and industry network we are able to identify transformative life science investments in under-ventured regions of the US and UK, building companies from scratch to create value and shared success. Our international management team has a track record of successfully partnering with scientists and entrepreneurs to develop highly innovative products for the global healthcare market. We leverage our extensive relationships, industry operating experience and a disciplined investment approach to add significant value to our portfolio companies and to generate strong returns on investment for our investors. We believe in working closely with the management of our portfolio companies to drive the translation of their research into world-class businesses. Our global network includes investment professionals, scientists, industry executives, health practitioners, policy experts, regulatory advisors and business development leaders. This strong network contributes significantly to the growth and development of our portfolio companies.

We are a venture capital firm specialised in seed investment for innovative early stage companies. BGV generally acts as lead investor. Our team is made up of life science experts and business analysts that can guide life science companies’ development throughout the entire research and development process. BioGeneration Ventures leverages its knowledge gained from working with a diverse network. This includes universities, early stage biotech companies and large pharma. We enable a range of sector-relevant expertise to build and accelerate product development and transform entrepreneurs and their companies to become attractive investment opportunities within the life sciences industry. Our Strategy BioGeneration Ventures (BGV) was launched in 2006. We manage over EUR 250 million across four funds. BGV invests in medical and healthcare innovations that have high potential to positively impact patients. BGV works with an ethos founded in sound novel science. We seek those innovations that have a truly differentiated scientific basis, supported by convincing experimental data. These innovations must be compelling and stand out in the global scientific arena. Only innovations that can address a significant unmet medical need are considered for investment. We aspire to invest in solutions that provide substantial healthcare impact. Progressing a project from discovery to clinical proof-of-concept requires a breadth of experience that founding teams usually do not have from the outset. Through our extensive network and experience we help founders build their companies to extend their capabilities. We guide our portfolio companies along their journey from the scientific discovery to a targeted product development track. Together with the founders, we seeks to shape the companies and define the objectives that enable a successful exit. Our partnerships BGV invests in partnerships with other professional investors in life sciences and has built relationships with various academic institutions (such as Leiden University), venture capital investors in the Netherlands, the EU and the US. Forbion: BGV operates a joint venture partnership with Forbion, a leading European life sciences venture capital fund. Mibiton: Mibiton provides loans to enable promising young life sciences companies to purchase equipment. BGV actively supports the investment activities with BGV Managing Partner Edward van Wezel serving as a member of the board. Our Investors: BGV has a broad investor base comprising private equity/wealth managers, pension funds, academic institutions, regional development funds and private investors.

We’re not just an investor. We’re all about being an active stakeholder. Identify: We are renown for identifying early stage technologies and start-ups. Our established network and expertise enable us to do so. Incubate: We run an incubation center for our early stage start-ups that need support in early growth stage. Accelerate: We act as business development managers for our portfolio companies. We help companies collaborate in the bio-ecosystem. Funding to IPO: We back our portfolio companies in the long run. We accompany them from the very start to their success. We take entrepreneurial ideas into reality. We have been investing in the past, present and into the future. Korea to Global: Using our global pharmaceutical network we source licensing & research collaboration deals for our portfolios. Korea to China: Through collaboration with our network in China we help value up our portfolio companies. Each year we host ‘China Korea Bio Business Networking Day’ to connect Korean biotechs with Chinese pharmaceuticals and buy-side investors. Korea to Vietnam: We invest in local Vietnam start-ups and build up platforms, formulate ecosystems to accommodate the growth of future industries. And beyond… We are creators and path makers We create synergy, matrix and we take the first step for others to follow.

Harmonix invests in technological breakthroughs that will help create a future for a healthy, operational, and peaceful civilization. The fund focuses on exceptional entrepreneurs and innovative healthcare, life sciences, and deep tech companies. Harmonix is a multi-disciplinary team comprising scientists, researchers, operators, entrepreneurs, and industry experts with over 70 years of cumulative experience. Our diverse team provides founders with deep technical, operating, industry, and advisory expertise to accelerate and commercialize the next generation of technological advances. Harmonix accelerates scientific discoveries to advance human health and technology. We invest in companies that have functional solutions to real world problems. The Harmonix Process We deploy an evidence-based due diligence framework in assessing companies. Research: We identify opportunities ripe for innovation and examine areas where current standards of R&D, care, treatment, or workflow processes are inadequate. We find companies with functional solutions to problems that can create real value for stakeholders. Invest: We assess not only the technical dimensions of a venture, including supporting proof-of-concept data but also founder-fund fit. Our team looks for founders with emotional intelligence and demonstrated capacity for leadership and integrity. Accelerate: We support founders in all realms of the entrepreneurial process, including technical, operational, and business development support. We offer access to advisors who provide a level of expertise that is unavailable to many early-stage scientific companies.

AI acceleration of scientific innovation and commercialization. Life Extension ventures invests in the two largest sectors in the world, People and Planet, where AI suddenly matters. Novel commercialization through marketplaces, networks, Web3, personalizations, payments, APIs, new go-to-markets and operations. Software, AI, and the power of the Internet will accelerate the adoption and monetization of science breakthroughs on human and planetary life. New infrastructure like SaaS, data platforms, OSs, LLMs, collaboration tools, storage, simulations, GenAI, visualization tools, security, workflow automation, Web3 and DAOs, or design tools to accelerate innovations. We target the infrastructure that accelerates the innovations. Software and AI are reinventing many industries bringing benefits to society and creating new category defining multibillion dollar companies; and now is the turn of climate, biology and health.